All In Biotech

Drug Trial Radar · NCT06214143

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

A Single-arm, Multi-center Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety, and Initial Efficacy of T3011 Herpesvirus Injection Combined With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Jan 11, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors

Conditions

  • Advanced Solid Tumors

Interventions

  • T3011 high doseBiological

    T3011 high dose: T3011 will be given intratumorally,Q2W; PD-1/PD-L1 inhibitor:Administered by intravenous infusion,3 mg/kg,Q2W

  • T3011 middle doseBiological

    T3011 middle dose: T3011 will be given intratumorally,Q2W; PD-1/PD-L1 inhibitor:Administered by intravenous infusion,3 mg/kg,Q2W

  • T3011 low doseBiological

    T3011 low dose: T3011 will be given intratumorally,Q2W; PD-1/PD-L1 inhibitor:Administered by intravenous infusion,3 mg/kg,Q2W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Approximately 2years
  2. Objective response rate(ORR)Time frame: Approximately 2years

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Anyang Cancer Hospital

    Anyang, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, China · Recruiting

  • Hunan cancer hospital

    Changsha, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Recruiting

  • Dongguan People's Hospital

    Dongwan, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    Guangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Ha’erbin, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Shandong cancer hospital

    Jinan, China · Recruiting

  • Jiangxi cancer hospital

    Nanchang, China · Recruiting

  • Guangxi Medical University Affiliated Cancer Hospital

    Nanning, China · Recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Shanghai Ninth People's Hospital

    Shanghai, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

    Shenzhen, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, China · Recruiting

  • Tianjin cancer hospital

    Tianjin, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Henan cancer hospital

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.